Modified GRF (1-29): FDA Status Explained and Evidence Boundaries
An evidence-led Modified GRF (1-29) review focused on fda status explained, human-study limits, regulatory context and claim verification.
Review Question
This evidence review asks approval attaches to a product and indication for Modified GRF (1-29). It is educational and does not provide dosing, treatment or purchasing advice.
Compound-Specific Context
Modified GRF (1-29) is a stabilized short-acting GHRH fragment commonly sold under the informal name CJC-1295 no DAC. It lacks the albumin-binding drug affinity complex.
Direct human outcome evidence tied unambiguously to commercial no-DAC material is sparse. Findings from CJC-1295 DAC cannot be transferred merely because sellers place both molecules under one name.
FDA Status Explained Analysis
FDA approval is based on a specific application, manufacturer, formulation, population and use. Studying a substance or allowing a trial to proceed is not approval.
Reviews should check Drugs@FDA and FDA compounding materials, then state approval history without implying endorsement of other preparations.
Where evidence is absent, the correct conclusion is uncertainty—not benefit, harm or equivalence by default.
Evidence Boundary Table
| Evidence layer | What this review can say |
|---|---|
| Identity | Modified GRF (1-29) is a stabilized short-acting GHRH fragment commonly sold under the informal name CJC-1295 no DAC. It lacks the albumin-binding drug affinity complex. |
| Human findings | Direct human outcome evidence tied unambiguously to commercial no-DAC material is sparse. Findings from CJC-1295 DAC cannot be transferred merely because sellers place both molecules under one name. |
| Boundary | A plausible GHRH mechanism is not proof of a particular exposure pattern, clinical benefit or long-term safety for a marketed no-DAC preparation. |
What the Evidence Supports
A plausible GHRH mechanism is not proof of a particular exposure pattern, clinical benefit or long-term safety for a marketed no-DAC preparation.
- Human, animal and cell findings must be labeled separately.
- A biomarker change is not automatically a body-composition, disease or functional outcome.
- Trial authorization is not FDA approval, and historical approval does not cover a new compounded product.
- Combination claims require evidence on the combination itself.
Source-Checking Questions
- Was the exact molecule and formulation identified?
- Was the study conducted in humans, and in which population?
- Did it measure hormones, clinical outcomes or both?
- Was follow-up adequate for the safety claim?
- Does the regulatory statement apply to this product and indication?